.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,667,801

« Back to Dashboard

Details for Patent: 5,667,801

Title: Sustained release heterodisperse hydrogel systems for insoluble drugs
Abstract:A sustained release pharmaceutical formulation includes a sustained release excipient including a gelling agent, an inert pharmaceutical diluent, an optional cationic cross-linking agent, and a medicament having moderate to poor solubility is disclosed. In certain embodiments, the sustained release excipient is granulated with a solution or suspension of a hydrophobic polymer in an amount effective to slow the hydration of the gelling agent when the formulation is exposed to an environmental fluid. In another embodiment, the tablet is coated with a hydrophobic polymer.
Inventor(s): Baichwal; Anand R. (Wappingers Falls, NY)
Assignee: Edward Mendell Co., Inc. (Patterson, NY)
Filing Date:May 21, 1996
Application Number:08/651,901
Claims:1. A sustained release oral solid dosage form for absorption of a therapeutically active medicament in the gastrointestinal tract, comprising:

an effective amount of a medicament having a solubility of less than about 10 g/l to render a therapeutic effect;

a sustained release excipient comprising a gelling agent comprising a heteropolysaccheride gum and a homopolysaccharide gum capable of cross-linking said heteropolysaccharide gum when exposed to an environmental fluid, the ratio of said heteropolysaccharide gum to said homopolysaccharide gum being from about 1:3 to about 3:1, an inert pharmaceutical diluent, the ratio of said inert diluent to said gelling agent being from about 1:8 to about 8:1; and a pharmaceutically acceptable cationic cross-linking agent capable of cross-linking with said gelling agent and increasing the gel strength when the dosage form is exposed to an environmental fluid; the ratio of said medicament to said gelling agent being from about 1:3 to about 1:8; said dosage form providing a sustained release of said medicament when exposed to an environmental fluid.

2. The oral solid dosage form of claim 1, wherein said heteropolysaccharide gum comprises xanthan gum and said homopolysaccharide gum comprises locust bean gum.

3. The oral solid dosage form of claim 2, wherein said cationic-cross linking agent comprises from about 0.5 to about 16 percent of the dosage form by weight.

4. The oral solid dosage form of claim 1, wherein said medicament has a solubility of less than about 1000 mg/l.

5. The oral solid dosage form of claim 4, wherein said medicament is a therapeutically effective dihydropyridine.

6. The oral solid dosage form of claim 1, wherein said medicament is selected from the group consisting of nifedipine, nimodipine, nivadipine, nitrendipine, nisolidipine, niludipine, nicardipine and felodipine.

7. The oral solid dosage form of claim 1, wherein said cationic cross-ling agent comprises an alkali metal or an alkaline earth metal sulfate, chloride, borate, bromide, citrate, acetate, or lactate.

8. The oral solid dosage form of claim 1, wherein said cationic cross-linking agent comprises calcium sulfate.

9. The oral solid dosage form of claim 1, which further comprises an effective amount of a pharmaceutically acceptable wetting agent for said medicament.

10. The oral solid dosage form of claim 8, wherein said wetting agent is polyethylene glycol.

11. The oral solid dosage form of claim 1, wherein said gelling agent, said inert diluent, and said cationic cross-linking agent are granulated with a hydrophobic material selected from the group consisting of an alkylcellulose, a copolymer of acrylic and methacrylic acid esters, waxes, shellac, zein, hydrogenated vegetable oils, and mixtures of any of the foregoing, prior to incorporation of said medicament, said hydrophobic material being included in said dosage form in an amount effective to slow the hydration of said gelling agent when exposed to an environmental fluid.

12. The oral solid dosage form of claim 11, wherein said hydrophobic material is ethylcellulose.

13. The oral solid dosage form of claim 1 which is a tablet.

14. The oral solid dosage form of claim 1 which is in granular form.

15. The oral solid dosage form of claim 14, which comprises a gelatin capsule containing a sufficient amount of said granules to provide an effective dose of said therapeutically active medicament.

16. The oral solid dosage form of claim 13 wherein at least part of a surface of said tablet is cooled with a hydrophobic material to a weight gain from about 1 to about 20 percent, by weight.

17. The oral solid dosage form of claim 14, wherein said granules are coated with a hydrophobic material to a weight gain from about 1% to about 20%.

18. The oral solid dosage form of claim 17, wherein said hydrophobic material is selected from the group consisting of an alkylcellulose, a copolymer of acrylic and methacrylic and esters, waxes, shellac, zein, hydrogenated vegetable oils, and mixtures of any of the foregoing, prior to incorporation of said medicament, said hydrophobic polymer being included in said dosage form in an mount effective to slow the hydration of said gelling agent when exposed to an environmental fluid.

19. The oral solid dosage form of claim 11 in tablet form, wherein at least part of a surface of said tablet is coated with a hydrophobic material to a weight gain of from about 1 to about 20 percent, by weight.

20. The oral solid dosage form of claim 19, wherein said mixture of sustained release excipient and said medicament are coated with a hydrophobic material prior to tableting.

21. The oral solid dosage form of claim 1 which is a tablet, said tablet further comprising a coating containing from about 10 to about 40 percent of the total amount of said medicament included in said dosage form.

22. The dosage form of claim 1, wherein said cationic cross-linking agent comprises form about 1% to about 20% of said dosage form, by weight.

23. The oral solid dosage form of claim 6, wherein said medicament is nifedipine.

24. The oral solid dosage form of claim 23, wherein the amount of nifedipine is 20 mg. 30 mg. 60 mg. or 90 mg.

25. The oral solid dosage form of claim 1, wherein said cationic cross-linking agent comprises from about 1% to about 2% of said excipient by weight.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc